


23rd Annual Prostate Cancer Foundation Scientific Retreat

October 27 - 29, 2016

La Costa Resort Carlsbad, California





GENERAL SESSIONS

Location: Costa Del Sol Ballroom

8:00 am	Registration	Costa Del Sol Foyer
<u>Welcome & Introduction</u> 1:30 PM - 1:40 PM		
	Howard Soule, PhD	
	Prostate Cancer Foundation	
	eatments in Prostate Cancer	
1:40 PM - 3:00 PM	Madavataw Jackwa Lawa MD	
	Moderator: Joshua Lang, MD	
	University of Wisconsin Carbone Cancer Center	
1:40 PM - 1:55 PM	<i>Biomarker-Driven Contexts of Use for a TRO Conjugate in Prostate Cancer</i> Joshua Lang, MD	P2 Antibody-Drug
	University of Wisconsin Carbone Cancer Center	
1:55 PM - 2:00 PM	Discussion	
2:00 PM - 2:15 PM	Understanding PREX2 and PTEN in Cancer Ramon Parsons, MD, PhD	
2:15 PM - 2:20 PM	Icahn School of Medicine at Mount Sinai Discussion	
2.13111 2.20111		
2:20 PM - 2:35 PM	<i>IRE1 Signaling Drives Prostate Cancer</i> Fahri Saatcioglu, PhD University of Oslo	
2:35 PM - 2:40 PM	Discussion	

2:40 PM - 2:55 PMROR-γ Nuclear Receptor as a New Therapeutic Target in Advanced
CRPC
Hongwu Chen, PhD
University of California, Davis2:55 PM - 3:00 PMDiscussion

Session 2: Prostate Cancer Research in the Netherlands

3:00 PM - 4:00 PM

Moderators: Guido Jenster, PhD Erasmus Medical Centre, The Netherlands Jack Schalken, PhD Radboud University Medical Centre, The Netherlands

- 3:00 PM 3:15 PM *Prostate Cancer Grading Beyond Gleason Score: 3D, Molecular and Clinical Perspective* Arno van Leenders, MD, PhD Erasmus Medical Centre, The Netherlands 3:15 PM - 3:20 PM Discussion
- 3:20 PM 3:35 PM *Epigenetics in Prostate Cancer: From Prognostication to Tailored Therapy* Wilbert Zwart, PhD Netherlands Cancer Institute, The Netherlands
 3:35 PM - 3:40 PM Discussion
 3:40 PM - 3:55 PM *Identifying Factors Governing Androgen Therapy Resistance Throp*
- 3:40 PM 3:55 PM *Identifying Factors Governing Androgen Therapy Resistance Through Transdifferentiation, an Organoid Approach* **Wouter Karthaus, PhD** Memorial Sloan Kettering Cancer Center 3:55 PM - 4:00 PM Discussion

Session 3: Radium for CRPC

4:00 PM - 5:20 PM

Moderator: James Gulley, MD, PhD National Cancer Institute

4:00 PM - 4:15 PM *Radium-223: Is Bone Targeted Therapy Meeting its Full Potential?* Michael Morris, MD Memorial Sloan Kettering Cancer Center 4:15 PM - 4:20 PM Discussion

4:20 PM - 4:35 PM	Radiation Induced Immunogenic Modulation: Insights for Combination Therapy James Gulley, MD, PhD National Cancer Institute
4:35 PM - 4:40 PM	Discussion
4:40 PM - 4:55 PM	<i>Targeting the Bone Compartment in Metastatic Prostate Cancer</i> Nora Navone, MD, PhD The University of Texas MD Anderson Cancer Center
4:55 PM - 5:00 PM	Discussion
5:00 PM - 5:15 PM	Radium-223: A Novel Approach to Prevention and Early Treatment of Bone Metastases from Prostate Cancer Robert Coleman, MD University of Sheffield, UK
5:15 PM - 5:20 PM	Discussion

<u>Session 4: Cancer Immunotherapy: Overcoming T Cell Exhaustion in the Tumor</u> <u>Microenvironment</u> 5:20 PM - 7:40 PM

Mederatory William Dedmand DhD
Moderator: William Redmond, PhD Providence Portland Medical Center
<i>Immune Suppression in the Tumor Microenvironment of Pancreatic Cancer</i> Sunil Hingorani, MD, PhD Fred Hutchinson Cancer Research Center
Discussion
DNA Repair, the Immune Response and Therapeutic Strategies Johann de Bono, MD, PhD Royal Marsden Hospital, UK
Discussion
<i>Overcoming T-cell Exhaustion in Prostate Cancer</i> Haydn Kissick, PhD Emory University School of Medicine
Discussion
<i>PD-1 Blockade in Prostate Cancer</i> Julie Graff, MD Oregon Health & Science University
Discussion

6:40 PM - 6:55 PM	<i>MMR Mutations and Microsatellite Instability in Prostate Cancer</i> Colin Pritchard, MD, PhD University of Washington
6:55 PM - 7:00 PM	Discussion
7:00 PM - 7:15 PM	DNA Damage Histological Score & Checkpoint Immunotherapy Mark Linch, MD, PhD University College London, UK
7:15 PM - 7:20 PM	Discussion
7:20 PM - 7:35 PM	<i>Novel Immunotherapy Strategies in Prostate Cancer</i> Sumit Subudhi, MD, PhD The University of Texas MD Anderson Cancer Center
7:35 PM - 7:40 PM	Discussion

<u>Dinner</u> 7:40 PM - 8:30 PM

Dinner Location: Costa Del Sol Patio

Poster Session and Dessert 8:30 PM - 11:00 PM

Poster Session and Dessert Location: Costa Del Sol ABC

6:30 AM - 7:30 AM Breakfast

Location: Costa Del Sol Patio

7:30 AM - 7:45 AM Move to Session

GENERAL SESSIONS Location: Costa Del Sol Ballroom



8:45 AM - 8:50 AM Break

<u>Session 5: Immunotherapy for Prostate Cancer</u> 8:50 AM - 10:10 AM

> Moderator: Howard Soule, PhD Prostate Cancer Foundation

Targeting Escape from the NKG2D Pathway with a Novel Cancer Vaccine Kai Wucherpfennig, MD, PhD Dana-Farber Cancer Institute
Discussion
<i>Improving PSMA Specific Eradication of Metastatic Prostate Cancer</i> <i>Using TGFβ Resistant CAR T Cells</i> Christopher Kloss, PhD University of Pennsylvania
Discussion
CAR T Cells for Treatment of Solid Tumors Saul Priceman, PhD City of Hope
Discussion
Marrow Infiltrating Lymphocytes: Their Biology and Clinical Implications Ivan Borrello, MD Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Discussion

<u>SPECIAL LECTURE</u> 10:10 AM - 10:50 AM

State of the Science 2016

Jonathan Simons, MD

Prostate Cancer Foundation

Introduced by Howard Soule, PhD Prostate Cancer Foundation

10:50 AM - 10:55 AM

Discussion

<u>KEYNOTE ADDRESS</u>

10:55 AM - 11:55 AM

Michael Milken

Founder and Chairman Prostate Cancer Foundation

Introduced by Stuart Holden, MD Prostate Cancer Foundation

Group Photo 11:55 AM - 12:10 PM

Location: TBD

Lunch 12:10 PM - 1:05 PM

Location: Costa Del Sol Patio

1:05 PM - 1:15 PM Move to Session 6

Location: Costa Del Sol Ballroom

<u>Session 6: Targeting DNA Repair Deficiency in Prostate Cancer</u> 1:15 PM - 3:10 PM Moderator: Bruce Montgomery, MD

University of Washington

1:15 PM - 1:45 PMSpecial Lecture: Targeting DNA Repair in Cancer Therapy
Alan D'Andrea, MD
Harvard Medical School1:45 PM - 1:50 PMDiscussion

1:50 PM - 2:05 PM	PARP Inhibitors: Opportunities and Challenges in Prostate Cancer Joaquin Mateo, MD The Institute of Cancer Research, UK
2:05 PM - 2:10 PM	Discussion
2:10 PM - 2:25 PM	Loss of DNA Repair in Prostate Cancer, Lessons from Breast and Ovarian Cancer Richard Kennedy, MD, PhD Queen's University Belfast
2:25 PM - 2:30 PM	Discussion
2:30 PM - 2:45 PM	<i>Platinum Agents in Homologous Recombination Deficiency</i> Bruce Montgomery, MD University of Washington Mark Pomerantz, MD Dana-Farber Cancer Institute
2:45 PM - 2:50 PM	Discussion
2:50 PM - 3:05 PM	<i>Aggressive Variant Prostate Cancers: Clinical and Molecular</i> <i>Characterization</i> Ana Aparicio, MD The University of Texas MD Anderson Cancer Center
3:05 PM - 3:10 PM	Discussion

<u>Session 7: Targeting Developmental Pathways in Prostate Cancer</u> 3:10 PM - 4:50 PM

Moderator: Carlos Moreno, PhD

Winship Cancer Institute at Emory University

3:10 PM - 3:25 PM	<i>Fundamentals of Canonical and Non-Canonical WNT Signaling in</i> <i>Cancer</i> Stuart Aaronson, MD Mount Sinai Hospital
3:25 PM - 3:30 PM	
3:30 PM - 3:45 PM	<i>Notch Signaling Promotes Prostate Cancer Metastasis</i> Li Xin, PhD Baylor College of Medicine
3:45 PM - 3:50 PM	Discussion
3:50 PM - 4:05 PM	Molecular Signatures in Circulating Prostate Cancer Cells Daniel Haber, MD, PhD Massachusetts General Hospital Cancer Center
4:05 PM - 4:10 PM	Discussion

4:10 PM - 4:25 PM SOX4 in PI3K/AKT and WNT Signaling in Prostate Cancer Carlos Moreno, PhD Winship Cancer Institute at Emory University
4:25 PM - 4:30 PM Discussion
4:30 PM - 4:45 PM Pharmacologically Targeting WNT Signals in Cancer Stem Cells Michael Kahn, PhD University of Southern California

4:45 PM - 4:50 PM Discussion

Special Announcement 4:50 PM - 5:00 PM

PyL Molecular Imaging Clinical Investigation

Mark Baker, JD

Progenics Pharmaceuticals

Dinner, Awards Ceremony, and Special Lecture 7:15 PM - 10:00 PM

Location: Costa Del Sol Ballroom

<u>Special Lecture:</u> <u>Genomic-Based Medicine and the Impact on Cancer</u> 8:15 PM - 8:35 PM

J. Craig Venter, PhD Human Longevity, Inc.

Introduced by: Michael Milken Prostate Cancer Foundation

PCF Awards Ceremony 8:45 PM - 9:30 PM

Featuring: <u>PCF Career Recognition Award</u>

Gary Gallick, PhD University of Texas MD Anderson Cancer Center

Presented by: Nora Navone, MD University of Texas MD Anderson Cancer Center Christopher Logothetis, MD University of Texas MD Anderson Cancer Center

Saturday, October 29, 2016

6:30 AM - 7:30 AM Breakfast

Location: Costa Del Sol Patio

7:30 AM - 7:45 AM Move to Session 8

GENERAL SESSIONS Location: Costa Del Sol Ballroom

<u>Session 8: New Platforms to Attack the Undruggable Targets</u> 7:45 AM - 9:50 AM

Moderator: Marco Gottardis, PhD Janssen Research & Development, LLC

- 7:45 AM 7:50 AM *Introduction* Marco Gottardis, PhD Janssen Research & Development, LLC
- 7:50 AM 8:05 AM *NK cells and Prostate Cancer* David Raulet, PhD University of California, Berkeley 8:05 AM - 8:10 AM Discussion
- 8:10 AM 8:25 AM *Targeting Recalcitrant Cancer Drivers using Cell-Penetrating Miniproteins* Gregory Verdine, PhD Fog Pharmaceuticals, Inc.
- 8:25 AM 8:30 AM Discussion
- 8:30 AM 8:45 AM
 PROTACs: Making the Problem Go Away via Induced Protein Degradation Craig Crews, PhD Yale University
 8:45 AM - 8:50 AM
 Discussion
- 8:50 AM 9:05 AM Drugging the Spliceosome: Therapeutic Modulation of Splicing in Human Malignancies Markus Warmuth, MD H3 Biomedicine, Inc.
 9:05 AM - 9:10 AM Discussion

Saturday, October 29, 2016

9:10 AM - 9:25 AM Development of a Pyrrole-Imidazole Polyamide for Treatment of Enzalutamide Resistant Prostate Cancer Nickolas Nickols, PhD, MD David Geffen School of Medicine at UCLA
9:25 AM - 9:30 AM Discussion
9:30 AM - 9:45 AM Expression Studies Implicate Neuroendocrine Prostate Cancer as a Novel Indication for Rovalpituzumab Tesirine – A Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC) Laura Saunders, PhD StemCentrx, Inc.
9:45 AM - 9:50 AM Discussion

Session 9: Precision Survivorship

9:50 AM - 11:05 AM

Moderators: Alicia Morgans, MD, MPH Vanderbilt University Medical Center Charles Ryan, MD University of California, San Francisco

- 9:50 AM 9:55 AM **Introduction** Alicia Morgans, MD, MPH Vanderbilt University Medical Center
- 9:55 AM 10:10 AM Cardiovascular Perils of Prostate Cancer Survivorship: A Personalized Approach to Prevention Javid Moslehi, MD, PhD Vanderbilt University Medical Center
- 10:10 AM 10:15 AM Discussion
- 10:15 AM 10:30 AM *ADT and the Brain: The Unwanted Target* Charles Ryan, MD University of California, San Francisco
- 10:30 AM 10:35 AM **Discussion**
- 10:35 AM 11:00 AM <u>Special Lecture:</u> On the Etiologies of Dementing Diseases Caused by Prions Stanley Prusiner, MD University of California, San Francisco

11:00 AM - 11:05 AM Discussion

Saturday, October 29, 2016

<u>Session 10: Circulating Tumor DNA: A Model for Public-Private Partnership</u> 11:05 AM - 12:10 PM

Moderator: Gerhardt Attard, MD, PhD

The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK


- 11:05 AM 11:10 AM *Introduction* Gerhardt Attard, MD, PhD The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK
- 11:10 AM 11:25 AM *Quantification of Circulating Tumor DNA* Francesca Demichelis, PhD University of Trento, Italy
- 11:25 AM 11:30 AM Discussion
- 11:30 AM 11:45 AM *Circulating Tumor DNA and Clinical Outcomes in mCPRC Patients Commencing AR-Targeted Therapy* **Alexander Wyatt, PhD** Vancouver Prostate Centre
- 11:45 AM 11:50 AM Discussion
- 11:50 AM 12:05 PM *Early Cancer Detection with Cell-Free Nucleic Acids: Challenges and Opportunities for Prostate Cancer* Mark Lee, MD, PhD GRAIL, Inc. 12:05 PM - 12:10 PM Discussion

<u>Closing Remarks</u> 12:10 PM - 12:15 PM

Howard Soule, PhD Prostate Cancer Foundation Jonathan Simons, MD Prostate Cancer Foundation

Meeting Adjourned

** A boxed lunch will be provided **



Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation) Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Jonathan Simons, MD (Prostate Cancer Foundation) Gerhardt Attard, MD, PhD (The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK) Johann de Bono, MD, PhD (Royal Marsden Hospital, UK) Marco Gottardis, PhD (Janssen Research & Development, LLC) James Gulley, MD, PhD (National Cancer Institute) Guido Jenster, PhD (Erasmus Medical Centre, The Netherlands) Joshua Lang, MD (University of Wisconsin Carbone Cancer Center) Bruce Montgomery, MD (University of Washington) Carlos Moreno, PhD (Winship Cancer Institute at Emory University) Alicia Morgans, MD, MPH (Vanderbilt University Medical Center) William Redmond, PhD (Providence Portland Medical Center) Charles Ryan, MD (University of California, San Francisco) Jack Schalken, PhD (Radboud University Medical Centre, The Netherlands) We deeply thank our Retreat supporters for providing funding for this educational initiative.



















